 Revenue expected between 16.0 million and 16.4 million Third consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30 Submitted a De Novo 510k Classification Request to FDA for Apollo ESGTM for weight loss and Apollo REVISETM for prior bariatric surgery revisions Principal investigators expected to present primary efficacy and safety endpoints from MERIT study in late October AUSTIN, TX ACCESSWIRE October 7, 2021 Apollo Endosurgery, Inc. Apollo NASDAQ:APEN, a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today preliminary unaudited financial results and corporate updates for the third quarter ended September 30, 2021, including anticipated revenue in the range of 16.0 million to 16.4 million and anticipated revenue growth in the range of 25 to 28 compared to third quarter 2020. Preliminary, Unaudited Third Quarter 2021 Financial Results Total revenue 16.0 million to 16.4 million Gross margin 54 to 56 Operating loss 4.1 million to 5.2 million Net loss 6.1 million to 7.3 million Non-GAAP adjusted EBITDA 2.1 million to 3.0 million We continue to successfully deliver against the priorities that we committed to early this year: specifically, to energize our business and drive near-term growth while laying the foundation for additional large-scale opportunities, said Chas McKhann, president and CEO. 